We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
05/3/2021 08:49 | Shareholders own the company directors manage the company, I'm amazed shareholders just rolling over and let Walmsley do what she wants. Cutting the dividend is a cardinal sin for income seekers. | montyhedge | |
05/3/2021 08:37 | To appoint her from within was a huge mistake, that is history, but watching this company being suffocated before being consumed is an absolute shocker. It is a wanton act of corporate murder! | wormhasturned | |
05/3/2021 08:17 | She wants to cut the dividend which upsets 99% of investors I would say. | montyhedge | |
05/3/2021 08:12 | Does the fool leading this company not listen to her largest shareholders, because if she did she might be aware that they disapprove of value destruction. I am sure that they do not solely think of the dividend contribution, but more the cost of that dividend to the stability of the company. Why she was appointed to the role of CEO is beyond, and it is clear she is a woman with a complete lack of empathy as she has not acknowledged that GSK will cease to exist post the separation. For a company that has amalgamated from the the Wellcome, SmithKline Beecham and Glaxo Organisation organisations, it is shocking to see the failures that management has achieved in terms of value to the company that resulted. Splitting may be obvious but at what cost! | wormhasturned | |
04/3/2021 16:25 | Beating Astra in percentage terms today. | montyhedge | |
04/3/2021 16:00 | ulvr does better in weaker markets, risk off. solid. | careful | |
04/3/2021 15:50 | ULVR is also up 1.6% | kev0856153 | |
04/3/2021 15:46 | If it closes above 1225p that's strong, if not may drift back tomorrow. | montyhedge | |
04/3/2021 15:43 | Hopefully today will end strong blue and above the recent range | supermarky | |
04/3/2021 15:28 | Good run today. | montyhedge | |
04/3/2021 15:20 | I wish, my dividend reinvestment plan it would work wonders. | montyhedge | |
04/3/2021 15:17 | who is still waiting for 1125? | eurofox | |
04/3/2021 15:00 | London, 15 January 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has temporarily paused the launch of its generic version of GlaxoSmithKline̵ Technicality with change of packaging: Hikma has submitted to the US FDA an amendment to its application. The amendment reflects enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA application. | tradermichael | |
04/3/2021 14:52 | I thought Hikma Pharma started the generic version of Advair in February? What's happened. | montyhedge | |
04/3/2021 14:00 | Yes if you paid 1375p unlucky. | montyhedge | |
04/3/2021 13:48 | Average price here at the moment 1204 | eurofox | |
04/3/2021 13:47 | Assuming your average is 1200p not substantially higher as is the case with most holders here. spud | spud | |
04/3/2021 11:24 | No vaccine for HSV-1 that I'm aware of, GSK offer acyclovir or the "newer" valaciclovir in tablet form. | essentialinvestor | |
04/3/2021 11:15 | Given how so many pension funds are invested in large/fairly large dividend paying stocks, I wonder if the Corporate Tax changes will have much of an impact on the trading strategy of said funds? Will more of them move towards buying high growth (and high R&D investment-focused companies), or will it just become another accounting exercise for the big players to navigate, whereby only the SME's pay anywhere close to 25% CT? I think I already know the answer to this one... Either way, hopefully GSK will no longer be languishing at that point, split or otherwise. | lovewinshatelosses | |
04/3/2021 11:03 | "At least its bosses promise another 80p for 2021. The intuitive response might be to tell Glaxo to stick it, but that would be silly. After all, with the share price down to £12.70, the dividend yields 6.3 per cent. Which leaves holding Glaxo’s shares feeling a bit like having herpes – easier to acquire than to be rid of, even though Glaxo does have a vaccine – but I am itching to be rid of them." Well, you may call it a rash (pun intended) decision, but I increased my GSK holding by 50% last week at just over 1200p. | mister md | |
04/3/2021 11:01 | All drug company share are down due to less operations be carried out .Don't panic guys time to buy Remember buy cheap sell on the up | notbitcoin | |
04/3/2021 10:58 | GSK's 130% capital allowances would more than offset the increase in CT. | ianood | |
04/3/2021 10:46 | GSK has a program to tackle Respiratory Syncytial Virus Infections. Vaccine trials are progressing well, with huge potential in India, Japan etc. to combat this seasonal epidemic. | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions